Inpatient GYN Surgery PostOp [1440]

| General | |
|---|--|
| Common Present on Admission Diagnosis | |
| | |
| [] Acidosis | Post-op |
| [] Acute Post-Hemorrhagic Anemia | Post-op |
| [] Acute Renal Failure | Post-op |
| [] Acute Respiratory Failure | Post-op |
| [] Acute Thromboembolism of Deep Veins of Lower Extremities | Post-op |
| [] Anemia | Post-op |
| [] Bacteremia | Post-op |
| [] Bipolar disorder, unspecified | Post-op |
| [] Cardiac Arrest | Post-op |
| [] Cardiac Dysrhythmia | Post-op |
| [] Cardiogenic Shock | Post-op |
| [] Decubitus Ulcer | Post-op |
| [] Dementia in Conditions Classified Elsewhere | Post-op |
| [] Disorder of Liver | Post-op |
| [] Electrolyte and Fluid Disorder | Post-op |
| [] Intestinal Infection due to Clostridium Difficile | Post-op |
| [] Methicillin Resistant Staphylococcus Aureus Infection | Post-op |
| [] Obstructive Chronic Bronchitis with Exacerbation | Post-op |
| [] Other Alteration of Consciousness | Post-op |
| [] Other and Unspecified Coagulation Defects | Post-op |
| [] Other Pulmonary Embolism and Infarction | Post-op |
| [] Phlebitis and Thrombophlebitis | Post-op |
| [] Protein-calorie Malnutrition | Post-op |
| Psychosis, unspecified psychosis type | Post-op |
| [] Schizophrenia Disorder | Post-op |
| [] Sepsis | Post-op |
| [] Septic Shock | Post-op |
| [] Septicemia | Post-op |
| [] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled | Post-op |
| Urinary Tract Infection, Site Not Specified | Post-op |
| [] Officery fract infection, Site Not Specified | 1 03t-0p |
| Elective Outpatient, Observation, or Admission (Single F | Response) |
| () Elective outpatient procedure: Discharge following routine recovery | Routine, Continuous, PACU & Post-op |
| () Outpatient observation services under general | Admitting Physician: |
| supervision | Patient Condition: |
| | Bed request comments: |
| | PACU & Post-op |
| () Outpatient in a bed - extended recovery | Admitting Physician: |
| | Bed request comments: |
| | PACU & Post-op |
| () Admit to Inpatient | Admitting Physician: |
| | Level of Care: |
| | Patient Condition: |
| | Bed request comments: |
| | Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and |
| | progress notes, I expect that the patient will need hospital |
| | services for two or more midnights. |
| | PACU & Post-op |
| | |
| Admission or Observation (Single Response) | |

| Patient has active outpatient status order on file | |
|---|---|
| () Admit to Inpatient | Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op |
| () Outpatient observation services under general supervision | Admitting Physician: Patient Condition: Bed request comments: PACU & Post-op |
| () Outpatient in a bed - extended recovery | Admitting Physician: Bed request comments: PACU & Post-op |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| () Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT |
| Admission (Single Response) Patient has active status order on file | |
| () Admit to inpatient | Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| () Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT |
| Transfer (Single Response) Patient has active inpatient status order on file | |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| () Return to previous bed Code Status @CERMSG(674511:)@ | Routine, Until discontinued, Starting S, Scheduling/ADT |
| [X] Code Status (Single Response) DNR and Modified Code orders should be placed by | by the responsible physician. |
| | Code Status decision reached by: Post-op |
| () DNR (Do Not Resuscitate) (Selection Required) [] DNR (Do Not Resuscitate) | Did the patient/surrogate require the use of an interpreter? Did the patient/surrogate require the use of an interpreter? Does patient have decision-making capacity? Post-op |

| Dulaulau. |
|---|
| Priority: |
| Reason for Consult? |
| Order? |
| Name of referring provider: |
| Enter call back number: |
| Reason for Consult: |
| Post-op |
| Did the patient/surrogate require the use of an interpreter? |
| Did the patient/surrogate require the use of an interpreter? |
| Does patient have decision-making capacity? |
| Modified Code restrictions: |
| Post-op |
| is NOT I understand that if the patient is NOT in a cardiopulmonary arrest, the selected treatments will NOT be provided. I |
| understand that all other unselected medically indicated |
| treatments will be provided. |
| Treatment Restriction decision reached by: |
| Specify Treatment Restrictions: |
| Post-op |
| . 55. 5p |
| |
| |
| Details |
| Once, Post-op |
| |
| Details |
| Details |
| Details |
| |
| Post-op |
| Increased observation level needed: |
| Post-op |
| Post-op |
| Increased observation level needed: |
| Post-op |
| 1 00.00 |
| |
| |
| Routine, Per unit protocol, Post-op |
| |
| Routine, Until discontinued, Starting S |
| Bathroom Privileges: with bathroom privileges |
| Post-op |
| Routine, Until discontinued, Starting S |
| Specify: Up in chair |
| Additional modifier: |
| This evening, Post-op |
| Routine, 4 times daily, Starting S+1 |
| ROUNDE 4 DIDES DAILY STATUDO 5+1 |
| |
| Specify: with assistance Post-op |
| |

| I | |
|---|--|
| [] Abdominal binder | Routine, Once |
| | Waking hours only? Nurse to schedule? |
| | Special Instructions: |
| | Post-op |
| [X] Encourage deep breathing and coughing | Routine, Every 2 hours while awake |
| | Until ambulatory, Post-op |
| [X] Incentive spirometry | Routine, Every 2 hours while awake |
| | Place at bedside. Encourage patient to use., Post-op |
| [] Intake and output | Routine, Every shift For 24 Hours, Post-op |
| [] K-pad to bedside | Routine, Until discontinued, Starting S |
| | Apply as needed to area of pain, Post-op |
| [] Saline lock IV | Routine, Continuous, Post-op |
| [] No other analgesia until PCA is discontinued | Routine, Until discontinued, Starting S, Post-op |
| Nursing POD 1 | |
| [] Remove dressing | Routine, Until discontinued, Starting S+1 |
| [] Nomove dicasing | Remove abdominal dressing or vaginal pack if present, |
| | Post-op |
| Nursing wound care | Routine, Daily, Starting S+1 |
| | Location: |
| | Site: |
| | Irrigate wound? |
| | Apply: |
| | Dressing Type: |
| | Clean incision with water, Post-op |
| [] Saline lock IV | Routine, Continuous, Starting S+1, Post-op |
| [] Discontinue IV | Routine, Once, Starting S+1 On POD 1 if patient is afebrile and tolerating diet, Post-op |
| [] Discontinue PCA on Post-Op day # 1 | Routine, Until discontinued, Starting S+1 Prior to discontinuing foley, Post-op |
| [X] Remove Foley catheter | Routine, Once, Starting S+1 |
| | D/C Foley in AM if urine is clear. DO NOT DC FOLEY IF ANTERIOR REPAIR OR BLADDER SURGERY., Post-op |
| [] Post-op voiding trial | Routine, Once, Starting S+1, Post-op |
| | reduitie, Office, clariting Of 1, 1 ost op |
| Notify | |
| [X] Notify Physician for vitals: | Routine, Until discontinued, Starting S |
| [A] Notiny i Tryoloidii Toi Vitalo. | Temperature greater than: 101 |
| | Temperature less than: |
| | Systolic BP greater than: 170 |
| | Systolic BP less than: 90 |
| | Diastolic BP greater than: 110 |
| | Diastolic BP less than: 60 |
| | MAP less than: |
| | Heart rate greater than (BPM): 120 |
| | Heart rate less than (BPM): 60 |
| | Respiratory rate greater than: 28 |
| | Respiratory rate less than: 10 |
| | SpO2 less than: |
| | And for urine output less than 30 milliliters per hour |
| Diet | |
| [X] NPO except ice chips | Diet effective now, Starting S |
| | NPO: Except Ice chips |
| | Pre-Operative fasting options: |
| | Until no longer nauseated, An NPO order without explicit |
| | exceptions means nothing can be given orally to the patient., |
| | Post-op |
| | |

| [] Diet - Clear Liquids | Diet effective now, Starting S Diet(s): Clear Liquids Advance Diet as Tolerated? IDDSI Liquid Consistency: Fluid Restriction: Foods to Avoid: Post-op |
|-------------------------|--|
| [X] Diet - | Diet effective midnight, Starting S+1 at 12:01 AM Diet(s): Advance Diet as Tolerated? Yes Target Diet: Regular Advance target diet criteria: IDDSI Liquid Consistency: Fluid Restriction: Foods to Avoid: Advance diet as tolerated 12 hours PostOP, Post-op |

IV Fluids

IV Fluids

| [X] lactated Ringer's infusion | 125 mL/hr, intravenous, continuous, Post-op |
|--|---|
| [] dextrose 5 % and lactated Ringer's infusion | 125 mL/hr, intravenous, continuous, Post-op |
| [] sodium chloride 0.9 % infusion | 125 mL/hr, intravenous, continuous, Post-op |
| [] dextrose 5%-0.9% sodium chloride infusion | 125 mL/hr, intravenous, continuous, Post-op |
| [] dextrose 5 % and sodium chloride 0.9 % with potassium | 125 mL/hr, intravenous, at 100 mL/hr, continuous, Post-op |
| chloride 20 mEg/L infusion | |

Peripheral IV Access

| [X] Initiate and maintain IV | |
|---------------------------------|--|
| [X] Insert peripheral IV | Routine, Once |
| [X] sodium chloride 0.9 % flush | 10 mL, intravenous, every 12 hours scheduled |
| [X] sodium chloride 0.9 % flush | 10 mL, intravenous, PRN, line care |

Medications

Antibiotics: cefazolin (ANCEF) for patients LESS than or EQUAL to 120 kg (Single Response)

| () cefazolin (ANCEF) IV | 2 g, intravenous, once, For 1 Doses, Post-op |
|-------------------------|--|
| | Per Med Staff Policy, R.Ph. will automatically renally dose this |
| | medication based on current SCr and CrCl values. |
| | Reason for Therapy: |

Antibiotics: cefazolin (ANCEF) for patients GREATER than 120 kg (Single Response)

| () cefazolin (ANCEF) IV | 3 g, intravenous, once, For 1 Doses, Post-op |
|--------------------------|--|
| | Per Med Staff Policy, R.Ph. will automatically renally dose this |
| | medication based on current SCr and CrCl values. |
| | Reason for Therapy: |

Antibiotics: if Penicillin or Beta-Lactam Allergic

If patient is Penicillin or Beta-Lactam Allergic: Choose ONE option from Section 1 and ONE option from Section 2. TWO agents MUST be selected for Core Measure compliance.

| ī |] Section 1 (Single Response) | |
|---|---|---|
| | () metronidazole (FLAGYL) IV | 500 mg, intravenous, once, For 1 Doses, Post-op For penicillin or beta-lactam allergic patients. Per Med Staff Policy, R.Ph. will automatically switch IV to equivalent PO dose when above approved criteria are satisfied: Reason for Therapy: |
| | clindamycin (CLEOCIN) IV - Recommended ONLY for patients with high risk for penicillin anaphylaxis that are culture isolate sensitive to Clindamycin. | 900 mg, intravenous, Administer over: 30 Minutes, once, For 1 Doses, Post-op For penicillin or beta-lactam allergic patients. Reason for Therapy: |

| [] Section 2 (Single Response) () levofloxacin (LEVAQUIN) IV | 500 ma. | intravenous, once, For 1 Doses, Post-op |
|--|--|--|
| (, =:::::::::::::::::::::::::::::::::::: | | cillin or beta-lactam allergic patients. |
| | | Staff Policy, R.Ph. will automatically renally dose this medication |
| | based of | n current SCr and CrCl values. |
| | Per Med | Staff Policy, R.Ph. will automatically switch IV to equivalent PO |
| | dose wh | en above approved criteria are satisfied: |
| | Reason | for Therapy: |
| () gentamicin (GARAMYCIN) IV | 5 mg/kg | , intravenous, Administer over: 30 Minutes, once, For 1 Doses, |
| | Post-op | |
| | For peni | cillin or beta-lactam allergic patients. |
| | Reason | for Therapy: |
| Mild Pain (Pain Score 1-3) (Single Response) |) | |
| () acetaminophen (TYLENOL) tablet | | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), |
| (, ==================================== | | Post-op |
| () ibuprofen (ADVIL, MOTRIN) tablet - Not red | commended | 600 mg, oral, every 6 hours PRN, mild pain (score 1-3), |
| in patients with eGFR LESS than 30 mL/min | | Post-op |
| kidney injury | | <u>-</u> |
| () traMADol (ULTRAM) tablet - Not recommend | ded in | 25 mg, oral, every 6 hours PRN, mild pain (score 1-3), |
| patients with eGFR LESS than 30 mL/min O | | Post-op |
| kidney injury | | Not recommended in patients with eGFR LESS than 30 |
| , , , | | mL/min OR in acutekidney injury. Not to exceed 400 mg/day. |
| | | Allowance for Patient Preference: |
| NALOXONE FOR OBGYN SURGERY POST O | P OPIOID PAI | N MEDICATIONS |
| | | |
| [X] naloxone (NARCAN) 0.4 mg/mL injection | | intravenous, PRN, respiratory depression, opioid reversal, L&D Pre-Delivery |
| | | Lad Fie-Delivery |
| Moderate Pain (Pain Score 4-6) (Single Response | onse) | |
| | | O tablet and every 2 become DDN mandagets noin (accord 4 C) |
| () acetaminophen-codeine (TYLENOL #3) 300 | -30 mg per | 2 tablet, oral, every 3 hours PRN, moderate pain (score 4-6), |
| tablet | | Post-op The use of codeins containing products is contraindicated in |
| | | The use of codeine-containing products is contraindicated in |
| | | notion to LECCILIAN 12 years of one to this notion to \(\sigma\)/ED 12 |
| | | patients LESS THAN 12 years of age. Is this patient OVER 12 |
| | | years of age? Y/N: |
| | | years of age? Y/N: Allowance for Patient Preference: |
| () HYDROcodone-acetaminophen (NORCO) 5 | i-325 mg per | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), |
| () HYDROcodone-acetaminophen (NORCO) 5 tablet | i-325 mg per | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op |
| tablet | | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: |
| | | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op |
| tablet | | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: |
| tablet () oxyCODONE-acetaminophen (PERCOCET) | | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet |) 5-325 mg | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme |) 5-325 mg | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O |) 5-325 mg | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme |) 5-325 mg | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O kidney injury |) 5-325 mg ended in DR in acute | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) |) 5-325 mg ended in DR in acute | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that |) 5-325 mg ended in DR in acute) an 30 mL/min A | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury |
| () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatments. |) 5-325 mg ended in DR in acute) an 30 mL/min A | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that |) 5-325 mg ended in DR in acute) an 30 mL/min A | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury |
| () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. | ended in OR in acute an 30 mL/min An ent of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. rative pain OR in the setting of coronary artery bypass graft |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR | ended in DR in acute an 30 mL/min An ent of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min Okidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 | ended in DR in acute an 30 mL/min An ent of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. rative pain OR in the setting of coronary artery bypass graft |
| () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O kidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection | ended in DR in acute an 30 mL/min An acute of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. Frative pain OR in the setting of coronary artery bypass graft |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O kidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection () For patients ages 17-64 AND weight | ended in DR in acute an 30 mL/min An acute of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. rative pain OR in the setting of coronary artery bypass graft |
| () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O kidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection () For patients ages 17-64 AND weight GREATER than or EQUAL to 50 kg AND | ended in DR in acute an 30 mL/min An acute of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. Frative pain OR in the setting of coronary artery bypass graft |
| tablet () oxyCODONE-acetaminophen (PERCOCET) per tablet () ketorolac (TORADOL) tablet - Not recomme patients with eGFR LESS than 30 mL/min O kidney injury () ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS that WARNING: Use is contraindicated for treatm (CABG) surgery. () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection () For patients ages 17-64 AND weight | ended in DR in acute an 30 mL/min An acute of perioper | years of age? Y/N: Allowance for Patient Preference: 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Allowance for Patient Preference: 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury AND/OR patients LESS than 17 years of age. Frative pain OR in the setting of coronary artery bypass graft |

| () traMADol (ULTRAM) tablet | 50 mg, oral, every 6 hours PRN, moderate pain (score 4-6), |
|--|--|
| | Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury. Not to exceed 400 mg/day. Allowance for Patient Preference: |
| Severe Pain (Pain Score 7-10) (Single Response) | |
| () HYDROcodone-acetaminophen (NORCO) 5-325 i tablet | ng per 2 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op Monitor and record pain scores and respiratory status. Allowance for Patient Preference: |
| () oxyCODONE-acetaminophen (PERCOCET) 5-32s per tablet | |
| () traMADol (ULTRAM) tablet | 100 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acute kidney injury. Not to exceed 400 mg/day. Allowance for Patient Preference: |
| () HYDROmorphone (DILAUDID) injection | 0.8 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op If patient is NPO or cannot tolerate Oral medication, administer the ordered injection. |
| () morPHINE injection | 4 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op And Notify MD. If patient is NPO or cannot tolerate Oral medication, administer the ordered injection. Allowance for Patient Preference: |
| Antiemetics | |
| [X] ondansetron (ZOFRAN) IV or Oral (Selection Req | · · · · · · · · · · · · · · · · · · · |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) IV or Oral or Recta | "Or" Linked Panel |
| [] promethazine (PHENERGAN) 12.5 mg IV | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
| [] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| Antiemetics | |
| [X] ondansetron (ZOFRAN) IV or Oral (Selection Req | |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) IV or Oral or Recta | |
| [] promethazine (PHENERGAN) injection | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, PACU & Post-op |
| | Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to |

| [] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, PACU & Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
|---|---|
| [] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, PACU & Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| Antiemetics | |
| [X] ondansetron (ZOFRAN) IV or Oral (Selection Re | quired) "Or" Linked Panel |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) IVPB or Oral or R | • |
| [] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB | 12.5 mg, intravenous, Administer over: 30 Minutes, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. |
| [] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| Itching: For Patients LESS than 70 years old (Sin | gle Response) |
| () diphenhydrAMINE (BENADRYL) tablet | 25 mg, oral, every 6 hours PRN, itching |
| () hydrOXYzine (ATARAX) tablet | 10 mg, oral, every 6 hours PRN, itching |
| (X) cetirizine (ZyrTEC) tablet | 5 mg, oral, daily PRN, itching |
| () fexofenadine (ALLEGRA) tablet - For eGFR LES 80 mL/min, reduce frequency to once daily as ne | |
| Bowel Care PRN (Single Response) | |
| () sennosides-docusate sodium (SENOKOT-S) 8.6 per tablet | -50 mg 2 tablet, oral, nightly PRN, constipation, Post-op |
| () magnesium hydroxide suspension - NOT RECOMMENDED FOR CHRONIC KIDNEY DIS STAGE 3 OR WORSE | 30 mL, oral, every 12 hours PRN, constipation, Post-op Do not give if patient is on hemodialysis or is in chronic renal failure. |
| () bisacodyl (DULCOLAX) EC tablet | 10 mg, oral, daily PRN, constipation, Post-op |
| () bisacodyl (DULCOLAX) suppository | 10 mg, rectal, daily PRN, constipation, Post-op |
| Bowel Care Scheduled | |
| [X] docusate sodium (COLACE) capsule | 100 mg, oral, 2 times daily, Post-op |
| Flatulence | |
| [] simethicone (MYLICON) chewable tablet | 160 mg, oral, 4 times daily PRN, flatulence, Post-op |
| Insomnia: For Patients GREATER than or EQUAL | to 70 years old (Single Response) |
| () ramelteon (ROZEREM) tablet | 8 mg, oral, nightly PRN, sleep |
| Insomnia: For Patients LESS than 70 years old (S | Single Response) |
| () zolpidem (AMBIEN) tablet | 5 mg, oral, nightly PRN, sleep |
| () ramelteon (ROZEREM) tablet | 8 mg, oral, nightly PRN, sleep |

VTE

DVT Risk and Prophylaxis Tool (Single Response) (Selection Required)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

() MODERATE Risk of DVT - Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| Moderate Risk (Selection Required) 1 Moderate risk of VTE | Routine, Once, PACU & Post-op |
|---|---|
| Moderate Risk Pharmacological Prophylaxis - S | |
| Patient (Single Response) (Selection Required) | ar groui |
| () Contraindications exist for pharmacologic prop BUT order Sequential compression device | nylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic | Routine, Once |
| prophylaxis | No pharmacologic VTE prophylaxis due to the following |
| | contraindication(s): |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| () Contraindications exist for pharmacologic prop AND mechanical prophylaxis | nylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic | Routine, Once |
| prophylaxis | No pharmacologic VTE prophylaxis due to the following |
| | contraindication(s): |
| [] Contraindications exist for mechanical | Routine, Once |
| prophylaxis | No mechanical VTE prophylaxis due to the following |
| | contraindication(s): |

(Selection Required)

Patient renal status: @CRCL@

For patients with CrCl GREATER than or EQUAL to 30mL/min, enoxaparin orders will apply the following recommended doses by weight:

Weight Dose

LESS THAN 100kg enoxaparin 40mg daily

100 to 139kg enoxaparin 30mg every 12 hours

GREATER THAN or EQUAL to 140kg enoxaparin 40mg every 12 hours

| subcutaneous Daily at 1700 [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 |
|--|---|
| | Indication(s): |
| () For CrCl GREATER than or EQUAL TO 30 n enoxaparin (LOVENOX) subcutaneous | nL/min - |
| [] enoxaparin (LOVENOX) injection | subcutaneous, Starting S+1 Indication(s): |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients with weight GREATER than 100 kg | 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Se Required) | lection |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s) |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |

Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| [] Moderate Risk (Selection Required) | |
|---------------------------------------|-------------------------------|
| [] Moderate risk of VTE | Routine, Once, PACU & Post-op |

| [] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Select Required) | tion |
|---|--|
| Contraindications exist for pharmacologic prop Order Sequential compression device | hylaxis - "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous |
| Contraindications exist for pharmacologic prop AND mechanical prophylaxis | hylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| [] Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Resp (Selection Required) | |
| Patient renal status: @CRCL@ | |
| For patients with CrCl GREATER than or EQU doses by weight: Weight Dose LESS THAN 100kg enoxaparin 40mg daily 100 to 139kg enoxaparin 30mg every 12 hours GREATER THAN or EQUAL to 140kg enoxap | |
| () For CrCl LESS than 30mL/min - enoxaparin (subcutaneous Daily at 1700 | (LOVENOX) |
| [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700 Indication(s): |
| () For CrCl GREATER than or EQUAL TO 30 m enoxaparin (LOVENOX) subcutaneous | nL/min - |
| [] enoxaparin (LOVENOX) injection | subcutaneous Indication(s): |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () HEParin (porcine) injection - For Patients with weight GREATER than 100 kg | 7,500 Units, subcutaneous, every 8 hours For patients with weight GREATER than 100 kg. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Sel Required) | ection |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain sequential compression device continuous | Routine, Continuous |
|) HIGH Risk of DVT - Surgical (Selection Required) | |

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

[] High Risk (Selection Required)

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

| [] Thigh than (Gelection Required) | |
|---|---|
| [] High risk of VTE | Routine, Once, PACU & Post-op |
| [] High Risk Pharmacological Prophylaxis - Surgion (Single Response) (Selection Required) | cal Patient |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | ponse) |
| Patient renal status: @CRCL@ | |
| For patients with CrCl GREATER than or EQU doses by weight: Weight Dose LESS THAN 100kg enoxaparin 40mg daily 100 to 139kg enoxaparin 30mg every 12 hour GREATER THAN or EQUAL to 140kg enoxap | |
| | |
| () For CrCl LESS than 30mL/min - enoxaparin subcutaneous Daily at 1700 | (LOVENOX) |
| [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |
| () For CrCl GREATER than or EQUAL TO 30 r | ` |
| enoxaparin (LOVENOX) subcutaneous | |
| [] enoxaparin (LOVENOX) injection | subcutaneous, Starting S+1 Indication(s): |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced |
| / | Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients with weight GREATER than 100 kg | 7,500 Units, subcutaneous, every 8 hours, Starting S+1 For patients with weight GREATER than 100 kg. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Se Required) | lection |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |

| | () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
|----|--|--|
| () | HIGH Risk of DVT - Non-Surgical (Selection Requ | ired) |
| | High Risk Definition Both pharmacologic AND mechanical prophylaxis One or more of the following medical conditions: Thrombophilia (Factor V Leiden, prothrombin varia or protein S deficiency; hyperhomocysteinemia; m Severe fracture of hip, pelvis or leg Acute spinal cord injury with paresis Multiple major traumas Abdominal or pelvic surgery for CANCER Acute ischemic stroke History of PE | ant mutations, anticardiolipin antibody syndrome; antithrombin, protein C |
| ī |] High Risk (Selection Required) | |
| ٠ | [] High risk of VTE | Routine, Once, PACU & Post-op |
| [| | Surgical |
| | () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| | () enoxaparin (LOVENOX) injection (Single Resp (Selection Required) | |
| | Patient renal status: @CRCL@ | |
| | doses by weight: Weight Dose LESS THAN 100kg enoxaparin 40mg daily 100 to 139kg enoxaparin 30mg every 12 hours GREATER THAN or EQUAL to 140kg enoxap | |
| | () For CrCl LESS than 30mL/min - enoxaparin (subcutaneous Daily at 1700 | (LOVENOX) |
| | [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700 Indication(s): |
| | () For CrCl GREATER than or EQUAL TO 30 m enoxaparin (LOVENOX) subcutaneous | nL/min - |
| | [] enoxaparin (LOVENOX) injection | subcutaneous Indication(s): |
| | () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| | () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op |
| | () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS |
| | weight < 50kg and age > 75vrs) | |
| | weight < 50kg and age > 75yrs) () heparin (porcine) injection - For Patients | than 50kg and age GREATER than 75yrs. |
| | weight < 50kg and age > 75yrs) () heparin (porcine) injection - For Patients with weight GREATER than 100 kg | |
| | () heparin (porcine) injection - For Patients | than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours |

[] Mechanical Prophylaxis (Single Response) (Selection

| | () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
|-----------------|---|--|
| | () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| $\overline{()}$ | HIGH Risk of DVT - Surgical (Hip/Knee) (Selection | n |
| () | Required) | |
| | High Risk Definition | |
| | Both pharmacologic AND mechanical prophylaxis | must be addressed. |
| | One or more of the following medical conditions: | |
| | | ant mutations, anticardiolipin antibody syndrome; antithrombin, protein C |
| | or protein S deficiency; hyperhomocysteinemia; m | yeloproliferative disorders) |
| | Severe fracture of hip, pelvis or leg Acute spinal cord injury with paresis | |
| | Multiple major traumas | |
| | Abdominal or pelvic surgery for CANCER | |
| | Acute ischemic stroke | |
| | History of PE | |
| | | |
| | | |
| | [] High Risk (Selection Required) [] High risk of VTE | Routine, Once, PACU & Post-op |
| | High Risk Pharmacological Prophylaxis - Hip or | · |
| | (Arthroplasty) Surgical Patient (Single Respons | |
| | (Selection Required) | |
| | () Contraindications exist for pharmacologic | Routine, Once |
| | prophylaxis | No pharmacologic VTE prophylaxis due to the following |
| | | contraindication(s): |
| | () aspirin chewable tablet | 162 mg, oral, daily, Starting S+1 |
| | () aspirin (ECOTRIN) enteric coated tablet | 162 mg, oral, daily, Starting S+1 |
| | () Apixaban and Pharmacy Consult (Selection R | · · · · |
| | [] apixaban (ELIQUIS) tablet | 2.5 mg, oral, 2 times daily, Starting S+1 Indications: VTE prophylaxis |
| | [] Pharmacy consult to monitor apixaban | STAT, Until discontinued, Starting S |
| | (ELIQUIS) therapy | Indications: VTE prophylaxis |
| | () enoxaparin (LOVENOX) injection (Single Resp | ponse) |
| | (Selection Required) | |
| | Patient renal status: @CRCL@ | |
| | For patients with CrCI GREATER than or EQL | JAL to 30mL/min, enoxaparin orders will apply the following recommended |
| | doses by weight: | |
| | Weight Dose | |
| | LESS THAN 100kg enoxaparin 40mg daily | |
| | 100 to 139kg enoxaparin 30mg every 12 hours | |
| | GREATER THAN or EQUAL to 140kg enoxap | arin 40mg every 12 nours |
| | | |
| | () For CrCl LESS than 30mL/min - enoxaparin | (LOVENOX) |
| | subcutaneous Daily at 1700 | · |
| | [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |
| | () For CrCl GREATER than or EQUAL TO 30 n | · · · |
| | enoxaparin (LOVENOX) subcutaneous | |
| | [] enoxaparin (LOVENOX) injection | subcutaneous, Starting S+1 |
| | () for denoting (ADIVTDA) intention | Indication(s): |
| | () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of |
| | | Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. |
| | | Contraindicated in patients LESS than 50kg, prior to surgery/invasive |
| | | procedure, or CrCl LESS than 30 mL/min |
| | | This patient has a history of or suspected case of Heparin-Induced |
| | | Thrombocytopenia (HIT): |
| | | |

| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
|--|---|
| () heparin (porcine) injection (Recommended | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM |
| for patients with high risk of bleeding, e.g. | Recommended for patients with high risk of bleeding, e.g. weight LESS |
| weight < 50kg and age > 75yrs) | than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients | 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| with weight GREATER than 100 kg | For patients with weight GREATER than 100 kg. |
| () Rivaroxaban and Pharmacy Consult (Selection Required) | |
| [] rivaroxaban (XARELTO) tablet for hip or | 10 mg, oral, daily at 0600 (TIME CRITICAL) |
| knee arthroplasty planned during this | Indications: VTE prophylaxis |
| admission | |
| [] Pharmacy consult to monitor rivaroxaban | STAT, Until discontinued, Starting S |
| (XARELTO) therapy | Indications: VTE prophylaxis |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 |
| | Indication: |
| () Pharmacy consult to manage warfarin | STAT, Until discontinued, Starting S |
| (COUMADIN) | Indication: |
|] Mechanical Prophylaxis (Single Response) (Sele | ection |
| Required) | |
| () Contraindications exist for mechanical | Routine, Once |
| prophylaxis | No mechanical VTE prophylaxis due to the following contraindication(s): |
| | PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

() MODERATE Risk of DVT - Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| | Moderate Risk (Selection Required) | |
|----------------------------------|--|---|
| | Moderate risk of VTE | Routine, Once, PACU & Post-op |
| | Moderate Risk Pharmacological Prophylaxis - So Patient (Single Response) (Selection Required) | urgical |
| | Contraindications exist for pharmacologic prople | hylaxis "And" Linked Panel |
| | BUT order Sequential compression device | |
| [] | , | Routine, Once |
| | prophylaxis | No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| [] | Place/Maintain sequential compression | Routine, Continuous |
| | device continuous | |
| () | Contraindications exist for pharmacologic propl AND mechanical prophylaxis | |
| [] | , , | Routine, Once |
| | prophylaxis | No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| [] | Contraindications exist for mechanical | Routine, Once |
| | prophylaxis | No mechanical VTE prophylaxis due to the following contraindication(s): |
| () | enoxaparin (LOVENOX) injection (Single Resp | . , |
| | (Selection Required) | , |
| | Patient renal status: @CRCL@ | |
| | • | AL to 30mL/min, enoxaparin orders will apply the following recommended |
| | doses by weight: Weight Dose | |
| | LESS THAN 100kg enoxaparin 40mg daily | |
| | 100 to 139kg enoxaparin 30mg every 12 hours | |
| | GREATER THAN or EQUAL to 140kg enoxapa | arin 40mg every 12 hours |
| | | |
| () | For CrCl LESS than 30mL/min - enoxaparin (I subcutaneous Daily at 1700 | LOVENOX) |
| [|] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |
| () | For CrCl GREATER than or EQUAL TO 30 m | maication(3). |
| - | enoxaparin (LOVENOX) subcutaneous | ` ' |
| [| enoxaparin (LOVENOX) subcutaneous enoxaparin (LOVENOX) injection | ` ' |
| () | | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 |
| () |] enoxaparin (LOVENOX) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of |
| () |] enoxaparin (LOVENOX) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. |
| () |] enoxaparin (LOVENOX) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. |
| () |] enoxaparin (LOVENOX) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced |
| () |] enoxaparin (LOVENOX) injection fondaparinux (ARIXTRA) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () () |] enoxaparin (LOVENOX) injection | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () () | penoxaparin (LOVENOX) injection fondaparinux (ARIXTRA) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS |
| () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. |
| () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg warfarin (COUMADIN) tablet | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. oral, daily at 1700, Starting S+1 Indication: |
| () () () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg warfarin (COUMADIN) tablet Pharmacy consult to manage warfarin (COUMADIN) | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. oral, daily at 1700, Starting S+1 Indication: STAT, Until discontinued, Starting S Indication: |
| () () () () () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg warfarin (COUMADIN) tablet Pharmacy consult to manage warfarin | L/min - subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. oral, daily at 1700, Starting S+1 Indication: STAT, Until discontinued, Starting S Indication: |
| () () () () () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg warfarin (COUMADIN) tablet Pharmacy consult to manage warfarin (COUMADIN) Mechanical Prophylaxis (Single Response) (Sele Required) Contraindications exist for mechanical | subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. oral, daily at 1700, Starting S+1 Indication: STAT, Until discontinued, Starting S Indication: ection Routine, Once |
| () () () () () () | heparin (porcine) injection heparin (porcine) injection heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) heparin (porcine) injection - For Patients with weight GREATER than 100 kg warfarin (COUMADIN) tablet Pharmacy consult to manage warfarin (COUMADIN) Mechanical Prophylaxis (Single Response) (Sele | subcutaneous, Starting S+1 Indication(s): 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. oral, daily at 1700, Starting S+1 Indication: STAT, Until discontinued, Starting S Indication: |

MODERATE Risk of DVT - Non-Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission [] Moderate Risk (Selection Required) Routine, Once, PACU & Post-op [] Moderate risk of VTE [] Moderate Risk Pharmacological Prophylaxis -Non-Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis -"And" Linked Panel Order Sequential compression device [] Contraindications exist for pharmacologic Routine, Once prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): [] Place/Maintain sequential compression Routine, Continuous device continuous () Contraindications exist for pharmacologic prophylaxis "And" Linked Panel AND mechanical prophylaxis [] Contraindications exist for pharmacologic Routine, Once prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): [] Contraindications exist for mechanical Routine, Once No mechanical VTE prophylaxis due to the following prophylaxis contraindication(s): () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) Patient renal status: @CRCL@ For patients with CrCl GREATER than or EQUAL to 30mL/min, enoxaparin orders will apply the following recommended doses by weight: Weight Dose LESS THAN 100kg enoxaparin 40mg daily 100 to 139kg enoxaparin 30mg every 12 hours GREATER THAN or EQUAL to 140kg enoxaparin 40mg every 12 hours () For CrCl LESS than 30mL/min - enoxaparin (LOVENOX) subcutaneous Daily at 1700 [] enoxaparin (LOVENOX) injection 30 mg, subcutaneous, daily at 1700

Indication(s):

subcutaneous Indication(s):

() For CrCl GREATER than or EQUAL TO 30 mL/min -

enoxaparin (LOVENOX) subcutaneous

[] enoxaparin (LOVENOX) injection

| () | fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily |
|--------------|--|---|
| () | , , , | If the patient does not have a history of or suspected case of |
| | | Heparin-Induced Thrombocytopenia (HIT), do NOT order this |
| | | medication. Contraindicated in patients LESS than 50kg, prior to |
| | | surgery/invasive procedure, or CrCl LESS than 30 mL/min |
| | | This patient has a history of or suspected case of Heparin-Induced |
| _ | | Thrombocytopenia (HIT): |
| () | heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () | heparin (porcine) injection (Recommended | 5,000 Units, subcutaneous, every 12 hours |
| | for patients with high risk of bleeding, e.g. | Recommended for patients with high risk of bleeding, e.g. weight LESS |
| _ | weight < 50kg and age > 75yrs) | than 50kg and age GREATER than 75yrs. |
| () | HEParin (porcine) injection - For Patients | 7,500 Units, subcutaneous, every 8 hours |
| | with weight GREATER than 100 kg | For patients with weight GREATER than 100 kg. |
| () | warfarin (COUMADIN) tablet | oral, daily at 1700 |
| <u> </u> | | Indication: |
| () | Pharmacy consult to manage warfarin | STAT, Until discontinued, Starting S |
| r 1 | (COUMADIN) | Indication: |
| IJ | Mechanical Prophylaxis (Single Response) (Sele | ection |
| 7) | Required) Contraindications exist for mechanical | Pouting Once |
| () | prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): |
| () | | Routine, Continuous |
| () | device continuous | Nouthe, Continuous |
|) ні | GH Risk of DVT - Surgical (Selection Required) | |
| | gh Risk Definition | |
| | oth pharmacologic AND mechanical prophylaxis r | must be addressed |
| | ne or more of the following medical conditions: | must be addressed. |
| | | nt mutations, anticardiolipin antibody syndrome; antithrombin, protein C |
| | protein S deficiency; hyperhomocysteinemia; my | |
| | evere fracture of hip, pelvis or leg | |
| | cute spinal cord injury with paresis | |
| | ultiple major traumas | |
| | dominal or pelvic surgery for CANCER | |
| Ac | tute ischemic stroke | |
| His | story of PE | |
| | | |
| F 1 | High Diels (Colonties Demoired) | |
| [] | High Risk (Selection Required) | Pouting Once DACIL & Doct on |
| | High risk of VTE | Routine, Once, PACU & Post-op |
| IJ | High Risk Pharmacological Prophylaxis - Surgica (Single Response) (Selection Required) | ai Patient |
| () | Contraindications exist for pharmacologic | Routine, Once |
| () | prophylaxis | No pharmacologic VTE prophylaxis due to the following |
| | propriyiaxis | contraindication(s): |
| () | enoxaparin (LOVENOX) injection (Single Resp | |
| () | (Selection Required) | |
| _ | Patient renal status: @CRCL@ | |
| | | |
| | For patients with CrCl GREATER than or EQUA | AL to 30mL/min, enoxaparin orders will apply the following recommended |
| | doses by weight: | |
| | Weight Dose | |
| | LESS THAN 100kg enoxaparin 40mg daily | |
| | 100 to 139kg enoxaparin 30mg every 12 hours | |
| | GREATER THAN or EQUAL to 140kg enoxapa | rin 40mg every 12 hours |
| | | |
| , | | |
| (| \ F== 0=011 F00 (!== 00=1 /: ! ! ! ! ! ! | OV/FNOV) |
| |) For CrCl LESS than 30mL/min - enoxaparin (I | LOVENOX) |
| | subcutaneous Daily at 1700 | <u> </u> |
| | | 30 mg, subcutaneous, daily at 1700, Starting S+1 |
| ī | subcutaneous Daily at 1700 [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |
| (| subcutaneous Daily at 1700 [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |

| [] enoxaparin (LOVENOX) injection | subcutaneous, Starting S+1 Indication(s): |
|--|--|
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients with weight GREATER than 100 kg | 7,500 Units, subcutaneous, every 8 hours, Starting S+1 For patients with weight GREATER than 100 kg. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| Mechanical Prophylaxis (Single Response) (Se Required) | election |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| HIGH Risk of DVT - Non-Surgical (Selection Reg | uired) |

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

| [] High Risk (Selection Required) | |
|--|---|
| [] High risk of VTE | Routine, Once, PACU & Post-op |
| [] High Risk Pharmacological Prophylaxis - Non-S | Burgical |
| Patient (Single Response) (Selection Required) | <u>, </u> |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following |
| propriylaxis | contraindication(s): |
| | PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Resp | oonse) |
| (Selection Required) | |

Patient renal status: @CRCL@

For patients with CrCl GREATER than or EQUAL to 30mL/min, enoxaparin orders will apply the following recommended doses by weight:

Weight Dose

LESS THAN 100kg enoxaparin 40mg daily

100 to 139kg enoxaparin 30mg every 12 hours

GREATER THAN or EQUAL to 140kg enoxaparin 40mg every 12 hours

() For CrCl LESS than 30mL/min - enoxaparin (LOVENOX) subcutaneous Daily at 1700

| [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700 Indication(s): |
|---|---|
| () For CrCl GREATER than or EQUAL TO 30 mL enoxaparin (LOVENOX) subcutaneous | · · · · · · · · · · · · · · · · · · · |
| [] enoxaparin (LOVENOX) injection | subcutaneous Indication(s): |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, PACU & Post-op |
| | If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. |
| | Contraindicated in patients LESS than 50kg, prior to surgery/invasive |
| | procedure, or CrCl LESS than 30 mL/min. |
| | This patient has a history of or suspected case of Heparin-Induced |
| () heparin (porcine) injection | Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op |
| () heparin (porcine) injection (Recommended | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op |
| for patients with high risk of bleeding, e.g. | Recommended for patients with high risk of bleeding, e.g. weight LESS |
| weight < 50kg and age > 75yrs) | than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients | 7,500 Units, subcutaneous, every 8 hours |
| with weight GREATER than 100 kg () warfarin (COUMADIN) tablet | For patients with weight GREATER than 100 kg. oral, daily at 1700, PACU & Post-op |
| () Warranin (OOOWADIN) tablet | Indication: |
| () Pharmacy consult to manage warfarin | STAT, Until discontinued, Starting S |
| (COUMADIN) | Indication: |
| [] Mechanical Prophylaxis (Single Response) (Sele Required) | CHOT |
| () Contraindications exist for mechanical | Routine, Once |
| prophylaxis | No mechanical VTE prophylaxis due to the following contraindication(s): |
| () Place/Maintain acquential compression | PACU & Post-op Routine, Continuous, PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, FACO & Post-op |
|) HIGH Risk of DVT - Surgical (Hip/Knee) (Selection | |
| Required) High Risk Definition | |
| Both pharmacologic AND mechanical prophylaxis m | nust be addressed. |
| One or more of the following medical conditions: | |
| | t mutations, anticardiolipin antibody syndrome; antithrombin, protein C |
| or protein S deficiency; hyperhomocysteinemia; mye Severe fracture of hip, pelvis or leg | eloproliterative disorders) |
| Acute spinal cord injury with paresis | |
| Multiple major traumas | |
| Abdominal or pelvic surgery for CANCER Acute ischemic stroke | |
| History of PE | |
| , | |
| [] High Risk (Selection Required) | |
| High risk of VTE | Routine, Once, PACU & Post-op |
| [] High Risk Pharmacological Prophylaxis - Hip or k | |
| (Arthroplasty) Surgical Patient (Single Response) (Selection Required) | |
| () Contraindications exist for pharmacologic | Routine, Once |
| prophylaxis | No pharmacologic VTE prophylaxis due to the following |
| () aspirin chewable tablet | contraindication(s): 162 mg, oral, daily, Starting S+1 |
| () aspirir (Tewable tablet () aspirin (ECOTRIN) enteric coated tablet | 162 mg, oral, daily, Starting S+1 |
| () Apixaban and Pharmacy Consult (Selection Red | <u> </u> |
| [] apixaban (ELIQUIS) tablet | 2.5 mg, oral, 2 times daily, Starting S+1 |
| [1] Pharmany consult to monitor anivehen | Indications: VTE prophylaxis STAT, Until discontinued, Starting S |
| [] Pharmacy consult to monitor apixaban (ELIQUIS) therapy | Indications: VTE prophylaxis |
| () enoxaparin (LOVENOX) injection (Single Responsable (Selection Required) | onse) |

Patient renal status: @CRCL@

For patients with CrCl GREATER than or EQUAL to 30mL/min, enoxaparin orders will apply the following recommended doses by weight:

Weight Dose

LESS THAN 100kg enoxaparin 40mg daily

100 to 139kg enoxaparin 30mg every 12 hours

GREATER THAN or EQUAL to 140kg enoxaparin 40mg every 12 hours

| () For CrCl LESS than 30mL/min - enoxaparin subcutaneous Daily at 1700 | (LOVENOX) |
|--|---|
| [] enoxaparin (LOVENOX) injection | 30 mg, subcutaneous, daily at 1700, Starting S+1 Indication(s): |
| () For CrCl GREATER than or EQUAL TO 30 enoxaparin (LOVENOX) subcutaneous | mL/min - |
| [] enoxaparin (LOVENOX) injection | subcutaneous, Starting S+1 Indication(s): |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () heparin (porcine) injection - For Patients with weight GREATER than 100 kg | 7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM For patients with weight GREATER than 100 kg. |
| () Rivaroxaban and Pharmacy Consult (Selection Required) | on |
| [] rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission | 10 mg, oral, daily at 0600 (TIME CRITICAL) Indications: VTE prophylaxis |
| [] Pharmacy consult to monitor rivaroxaban (XARELTO) therapy | STAT, Until discontinued, Starting S Indications: VTE prophylaxis |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Se Required) | election |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |

Rh Negative Mother

Nursing

[X] Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody results) IM within 72 hours of delivery. Routine, Until discontinued, Starting S, Post-op

Labs

[] Fetal Screen

Conditional Frequency For 1 Occurrences Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op

| [] Rhogam Type and Screen | Once, Post-op |
|--|---|
| Medication | |
| [] rho(D) immune globulin (HYPERRHO/RHOGAM) injection | 300 mcg, intramuscular, PRN, Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody results) IM within 72 hours of delivery., For 1 Doses, Post-op |
| Labs Tomorrow | |
| Hematology | |
| [] CBC with differential | AM draw, Starting S+1 For 1 Occurrences, Post-op |
| Hemoglobin and hematocrit | Once, Post-op |
| Chemistry | |
| Basic metabolic panel | Once, Post-op |
| [] Dasic metabolic panel | Office, Post-op |
| Consults For Physician Consult orders use sidebar | |
| | Consult Reason: |
| For Physician Consult orders use sidebar Ancillary Consults [] Consult to Case Management | Post-op |
| For Physician Consult orders use sidebar Ancillary Consults | |
| For Physician Consult orders use sidebar Ancillary Consults [] Consult to Case Management | Post-op Reason for Consult: |
| For Physician Consult orders use sidebar Ancillary Consults [] Consult to Case Management [] Consult to Social Work | Post-op Reason for Consult: Post-op Reasons for referral to Physical Therapy (mark all applicable) Are there any restrictions for positioning or mobility? Please provide safe ranges for HR, BP, O2 saturation(if values are very abnormal): Weight Bearing Status: |
| For Physician Consult orders use sidebar Ancillary Consults [] Consult to Case Management [] Consult to Social Work [] Consult PT Eval and Treat | Post-op Reason for Consult: Post-op Reasons for referral to Physical Therapy (mark all applicable) Are there any restrictions for positioning or mobility? Please provide safe ranges for HR, BP, O2 saturation(if values are very abnormal): Weight Bearing Status: Post-op Reason For Consult? Purpose/Topic: |